Blog - Page 903 of 5753 - QualityStocks

TuesdayNov 01, 2022 1:23 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of independent review board (“IRB”) approval for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. The 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study will be conducted in current cigarette smokers, wherein each person will visit the laboratory to be dosed three times over a period of weeks. Only one oral nicotine pouch (either DehydraTECH-nicotine; On! brand manufactured by Altria; or Zyn brand manufactured by Swedish Match) will be administered during each visit and evaluated. Predetermined questionnaires for subjective…

TuesdayNov 01, 2022 12:56 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in Boston. Cybin director of neuropharmacology Amy Reichelt, PhD, will present during the event; her presentation, titled “CYB004 — Modifications to DMT to Enhance its Therapeutic Potential,” includes an overview of the preclinical data for CYB004, Cybin’s deuterated dimethyltryptamine (DMT) program and the advantages of deuteration on its therapeutic effect. Reichelt’s presentation will begin at 1:15 p.m. ET today.“I am delighted to be…

TuesdayNov 01, 2022 12:33 pm

QualityStocksNewsBreaks – Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) Engages IMS for Investor Communications Expertise

Hillcrest (CSE: HEAT) (OTCQB: HLRTF), a clean technology company developing transformative power conversion technologies and control system solutions for next-generation electrical systems, today announced that it has retained IMS Investor Relations (“IMS”) effective Oct. 1, 2022. According to the update, IMS will provide capital markets consulting, corporate communications and strategic investor outreach. “Hillcrest’s highly adaptive power conversion technology is at an exciting stage of growth and development, evidenced in part by our two recent strategic partnerships including a global tier 1 automotive supplier,” said Hillcrest Chief Executive Officer Don Currie. “IMS is a respected firm with proven sector experience, and…

TuesdayNov 01, 2022 12:00 pm

Tampa Alternative Products Expo To Offer A Festive Vibe Amongst Business Networking

Exhibitors, speakers, businesses, CBD and alternative products vendors, and researchers, are all invited to attend the Tampa Alternative Products Expo 2022 at the Tampa Convention Center. With over 10,000 attendees, 300+ vendors, and 20+ speakers per event, the Expo will exude a festival-like vibe for Tampa's CBD, cannabis, and vape communities. The event is organized by ZJ Events, with a reputation for managing the nation's largest CBD & Hemp Summits. The Alt Pro Expo team has expanded into the alternative products sector, which is currently disrupting traditional markets. This product category includes kratom, nootropics, vapes & nicotine replacements, energy beverages,…

TuesdayNov 01, 2022 11:15 am

Mullen Automotive Inc. (NASDAQ: MULN) ‘Strikingly Different’ Test Drive Tour Shines Spotlight on Mullen FIVE

Mullen’s U.S. test drive tour added additional dates, locations based on overwhelming response Tour provides hands-on opportunity to see the Mullen FIVE Second leg of tour, which will feature the Mullen FIVE RS, already in the planning stage Mullen Automotive (NASDAQ: MULN) is ending the year with a bang with its Mullen FIVE “Strikingly Different” U.S. Test Drive Tour (https://ibn.fm/eDWyL). The tour, which features the company’s innovative Mullen FIVE, kicked off in October. With additional locations added based on demand, the tour now has eight stops scheduled throughout November and December. “When we announced the [first] location, we received an…

TuesdayNov 01, 2022 10:41 am

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Files for Patent Protection on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

Odyssey Health (OTC: ODYY) has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As previously announced, Odyssey’s recently completed phase I study to treat concussion successfully used Odyssey’s Nasal Device and drug combination. “We were very pleased with the functionality and performance of the Nasal Device during the phase I study and its administration of Odyssey’s PRV-002 concussion drug,” said Michael Redmond, CEO of Odyssey. “The ability to get drugs for neurological conditions delivered directly into the brain rapidly at effective levels while simultaneously having less concern for side effects…

TuesdayNov 01, 2022 10:30 am

Correlate Infrastructure Partners Inc. (CIPI) In Strong Position, as IRA Unleashes Funding Opportunities, and Evidence Shows U.S. Dramatic Turn Toward Renewables

Correlate Infrastructure Partners Inc. is a company that helps commercial real estate industry clients make the transition to climate-friendly energy sources in highly affordable ways Climate friendliness has increasingly occupied the attention of international governments amid reports of growing extreme weather events and forecasts for devastating impacts on global human lifestyles as well as on other living creatures International agreement on climate-friendly energy use transitions in 2015 has established a framework for goals, but experts fear the goals aren’t being met Despite a slow response to climate change goals, a Bloomberg analysis notes growing optimism for renewable energy adoption as…

TuesdayNov 01, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Focusing on Execution and Brand Integration Following Successful Period of Strategic Investment

Flora Growth recently participated in an earnings call in which the management team discussed the company’s financials as well as its growth strategy and outlook for the remainder of fiscal 2022 as well as 2023 The company noted it had exited a period of investment and is now focusing on execution The period of investment saw the company acquire synergistic brands that, collectively, create a direct-to-consumer house of brands, enabling the company to enter nearly any target market regardless of the legal status of cannabis The company also invested in the infrastructure necessary for the activation of its cultivation facility…

MondayOct 31, 2022 1:51 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross the blood-brain barrier to target tumors directly. Tested against Dox in cancer cells, Berubicin showed a greater capacity to destroy or damage the cancers. In models evaluating intracranial gliomas, Berubicin showed a greater capacity to prolong life than temozolomide, another standard of care for GBM,”…

Site Search

Company Search